Physiological changes in the critically Ill patient with sepsis

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 1991-1995

  Hosein, Shaun ^a   Udy, Andrew A ^a,b   Lipman, Jeffrey ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Critical care; Physiology; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; CYTOCHROME P450 3A4;

ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; HEART OUTPUT; HUMAN; INTERSTITIUM; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; SEPSIS; SEPTIC SHOCK;

ANTI-INFECTIVE AGENTS; CARDIOVASCULAR SYSTEM; CRITICAL ILLNESS; HUMANS; INFLAMMATION; KIDNEY; LIVER; SEPSIS;

EID: 84855244376     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808248     Document Type: Article

References (46)

1. Bagshaw, S.M.; Bellomo, R.; Jacka, M.J.; Egi, M.; Hart, G.K.; George, C. The impact of early hypoglycemia and blood glucose variability on outcome in critical illness. Crit. Care, 2009, 13(3), R91.
2. Finfer, S.; Bellomo, R.; Lipman, J.; French, C.; Dobb, G.; Myburgh, J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med., 2004, 30(4), 589-596.
3. Finfer, S.; Bellomo, R. The ANZICS Clinical Trials Group 1994- 2001: developing a unique research strategy. World Federation J. Crit. Care Congr. Edn., 2001, 14-17.
4. van der Poll, T.; Opal, S.M. Host-pathogen interactions in sepsis. Lancet Infect. Dis., 2008, 8(1), 32-43.
5. Annane, D.; Bellissant, E.; Cavaillon, J.M. Septic Shock. Lancet, 2005, 365(9453), 63-78.
6. Levy, M.M.; Fink, M.P.; Marshall, J.C.; Abraham, E.; Angus, D.; Cook, D.; Cohen, J.; Opal, S.M.; Vincent, J.L.; Ramsay G, 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med., 2003, 29(4), 530-538.
7. Nduka, O.O.; Parrillo, J.E. The pathophysiology of septic shock. Crit. Care Clin., 2009, 25(4), 677-702.
8. Castellheim, A.; Brekke, O.L.; Espevik, T.; Harboe, M.; Mollnes, T.E. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J. Immunol., 2009, 69(6), 479-91.
9. Cinel, I.; Dellinger, R.P. Advances in pathogenesis and management of sepsis. Curr. Opin. Infect. Dis., 2007, 20(4), 345-352.
10. Ulloa, L.; Tracey, K.J. Thècytokine profile': a code for sepsis. Trends Mol. Med., 2005, 11(2), 56-63.
11. Cinel, I.; Opal, S.M. Molecular biology of inflammation and sepsis: a primer. Crit. Care Med., 2009; 37(1), 291-304.
12. Brealey, D.; Brand, M.; Hargreaves, I.; Heales, S.; Land, J.; Smolenski, R.; Davies, N.A.; Cooper, C.E.; Singer, M. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet, 2002, 360(9328), 219-223.
13. Crouser, E.D.; Julian, M.W.; Blaho, D.V.; Pfeiffer, D.R. Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit. Care Med., 2002, 30(2), 276-284.
14. Bone, R.C. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann. Intern Med., 1996, 125(8), 680-687.
15. Rittirsch, D.; Flierl, M.A.; Ward P.A. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol., 2008, 8(10), 776-787.
16. Frank, O. Zur Dynamik des Herzmuskels. J. Biol., 1895, 32, 370-447.
17. Starling, E. Linacre Lecture on the Law of the Heart, 1918.
18. Gosling, P.; Sanghera, K.; G Dickson G. Generalized vascular permeability and pulmonary function in patients following serious trauma. J. Trauma, 1994, 36(4), 477-481.
19. Nuytinck, H.K.; Offermans, X.J.; Kubat, K.; Goris, J. A. Wholebody inflammation in trauma patients. An autopsy study. Arch Surg., 1988, 123(12), 1519-1524.
20. Roberts, J.A.; Lipman, J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet, 2006, 45(8), 755-773.
21. Roberts, J.A.; Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med., 2009, 37(3), 840-851.
22. Joynt, G.M.; Lipman, J.; Gomersall, C.D.; Young, R.J.; Wong, E.L.; Gin, T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J. Antimicrob. Chemother., 2001, 47(4), 421-429.
23. Landry, D.W.; Levin, H.R.; Gallant, E.M.; Ashton, R.C. Jr.; Seo, S.; D'Alessandro, D.; Oz, M.C.; Oliver, J.A. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation, 1997, 95(5), 1122-1125.
24. Knuefermann, P.; Boehm O., Baumgarten, G., Zacharowski, K. Sepsis-induced vasoplegia--is vasopressin V1A-receptor a new target? Crit. Care Med., 2008, 36(8), 2468-2469.
25. Calvin, J.E.; Driedger A.A.; Sibbald, W.J. An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. Chest, 1981, 80(5), 579-586.
26. Parker, M.M., Shelhamer, J.H.; Bacharach, S.L.; Green, M.V.; Natanson, C.; Frederick, T.M.; Damske, B.A.; Parrillo, J.E. Profound but reversible myocardial depression in patients with septic shock. Ann. Intern. Med., 1984, 100(4), 483-490.
27. Poelaert, J.; Declerck, C.; Vogelaers, D.; Colardyn, F.; Visser, C. A. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med., 1997, 23(5), 553-560.
28. Reilly J.M.; Cunnion, C.E.; Burch-Whitman, C.; Parker, M.M.; Shelhamer, J.H.; Parrillo, J.E. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest, 1989, 95(5), 1072-1080.
29. Bagshaw, S.M.; George, C.; Bellomo, R. Early acute kidney injury and sepsis: a multicentre evaluation. Crit. Care, 2008, 12(2), R47.
30. Sun, H.; Frassetto, L.; Benet, L.Z. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther., 2006, 109(1-2), 1-11.
31. Choi, G., Gomersall C. G., Tian, Q., Joynt, G. M., Freebairn R. Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med., 2010, 37(7), 2268-2282.
32. Martin, J.H.; Fay, M.F.; Udy, A.A.; Roberts, J.A.; Kirkpatrick, C.M.J.; Ungerer, J.; Lipman, J. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med. J., 2010, in press,
33. Lipman, J., Wallis, S. C.; Boots, R. J. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth. Analg., 2003, 97(4), 114-154.
34. Udy, A.A.; Putt, M.; Boots, R.J.; Lipman, J. ARC - Augmented renal clearance. Curr. Pharm. Biotech., 2010, in press.
35. Byl, B.; Roucloux, I.; Crusiaux, A.; Dupont, E.; Devière, J. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patient. Gastroenterology, 1993, 104(5), 1492-1497.
36. Moreau, R.; Lee, S.S.; Soupison, T.; Roche-Sicot, J.; Sicot, C. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. J. Hepatol., 1988, 7(1), 98-105.
37. Albillos, A.; Rossi I.; Cacho, G.; Martínez, M.V.; Millán, I.; Abreu, L.; Barrios, C.; Escartín, P. Enhanced endotheliumdependent vasodilation in patients with cirrhosis. Am. J. Physiol., 1995, 268(3 Pt 1), G459-64.
38. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med., 2005, 352(21), 2211-2221.
39. Spriet, I.; Meersseman, W.; de Hoon, J.; von Winckelmann, S.; Wilmer, A.; Willems, L. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med., 2009, 35(4), 603-612.
40. Thomson, P.D.; Melmon, K.L.; Richardson, J.A.; Cohn, K.; Steinbrunn, W.; Cudihee, R.; Rowland, M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann. Intern. Med., 1973, 78(4), 499-508.
41. Haas, C.E.; Kaufman, D.C.; Jones, C.E.; Burstein, A.H.; Reiss, W. Cytochrome P450 3A4 activity after surgical stress. Crit. Care Med., 2003, 31(5), 1338-1346.
42. Gustot, T.; Durand, F.; Lebrec, D.; Vincent, J.L.; Moreau, R. Severe sepsis in cirrhosis. Hepatology, 2009, 50(6), 2022-2033.
43. Foreman, M.G.; Mannino, D.M.; Moss, M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest, 2003, 124(3), 1016-1020.
44. Fernandez, J.; Navasa, M.; Gómez, J.; Colmenero, J.; Vila, J.; Arroyo, V.; Rodés, J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology, 2002, 35(1), 140-148.
45. Joukhadar, C.; Frossard, M.; Mayer, B.X.; Brunner, M.; Klein, N.; Siostrzonek, P.; Eichler, H.G.; Müller, M. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit. Care Med., 2001, 29(2), 385-391.
46. Roberts, J.A.; Roberts, M.S.; Robertson, T.A.; Dalley, A.J.; Lipman, J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit. Care Med., 2009, 37(3), 926-933.